Insights
Media Center
Latest Therapy Updates
- Head-to-Head Against Nivolumab: First Patient Enrolled in the International Phase III Trial of First-Line Cadonilimab for Gastric Cancer
- The statistically significant positive OS results of ivonescimab versus pembrolizumab in the first-line treatment of PD-L1-positive NSCLC (HARMONi-2 study) were announced at WCLC 2026
- Fudan Cancer Team’s Research on Preventing Nausea and Vomiting During Cancer Immunotherapy Published in an International Journal
- Professor Chen Yue’s team from the Department of Nuclear Medicine, Southwest Medical University Affiliated Hospital published prospective clinical research results
- Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Page 1 of 12
What could this mean for your care?
A promising treatment raises a personal question: could it be an option for you? Chirona helps you explore that question with the right specialists.
Start a case reviewHow our service worksUnderstand your options
Explore the treatments relevant to your diagnosis, previous care and priorities.
Bring your case to specialists
We help organise your medical records and coordinate a professional assessment of suitability and access.
Plan the next step together
If a treatment path is appropriate, we help coordinate consultations, hospital arrangements and continuity of care.